SK Life Science Labs Experts Unveil Latest Scientific Findings at Keystone Symposia on Epigenetic Mechanisms and Cancer Treatment, and the 2nd Annual Molecular Glue Drug Development Summit
February 08, 2024 09:10 ET
|
SK Biopharmaceuticals Co., Ltd.
KING OF PRUSSIA, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, Co., Ltd., showcased its cutting-edge targeted...
SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit
October 31, 2023 09:00 ET
|
SK Biopharmaceuticals Co., Ltd.
KOREA and KING OF PRUSSIA, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, today will present preclinical data...
SK Biopharmaceuticals’ Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 12, 2023 13:00 ET
|
SK Biopharmaceuticals Co., Ltd.
KOREA and KING OF PRUSSIA, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of...
SK Biopharmaceuticals’ Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference
September 26, 2023 10:01 ET
|
SK Biopharmaceuticals Co., Ltd.
KOREA and KING OF PRUSSIA, Pa., Sept. 26, 2023 (GLOBE NEWSWIRE) -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of...